We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,576 hedge funds and large institutions have $90.9B invested in Bristol-Myers Squibb in 2016 Q2 according to their latest regulatory filings, with 114 funds opening new positions, 576 increasing their positions, 640 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more first-time investments, than exits

New positions opened: 114 | Existing positions closed: 43

39% more funds holding in top 10

Funds holding in top 10: 79110 (+31)

21% more call options, than puts

Call options by funds: $785M | Put options by funds: $647M

16% more capital invested

Capital invested by funds: $78B → $90.9B (+$12.9B)

3% more funds holding

Funds holding: 1,5231,576 (+53)

1.35% less ownership

Funds ownership: 75.29%73.94% (-1.4%)

10% less repeat investments, than reductions

Existing positions increased: 576 | Existing positions reduced: 640

Holders
1,576
Holders Change
+53
Holders Change %
+3.48%
% of All Funds
42.05%
Holding in Top 10
110
Holding in Top 10 Change
+31
Holding in Top 10 Change %
+39.24%
% of All Funds
2.93%
New
114
Increased
576
Reduced
640
Closed
43
Calls
$785M
Puts
$647M
Net Calls
+$138M
Net Calls Change
-$29.5M
Name Holding Trade Value Shares
Change
Change in
Stake
NIM
251
Northeast Investment Management
Massachusetts
$20.6M +$2.01M +28,494 +11%
TMAM
252
Tokio Marine Asset Management
Japan
$20.2M -$388K -5,497 -2%
CIA
253
CCM Investment Advisers
South Carolina
$19.8M -$25.6K -363 -0.1%
AAF
254
Andra AP-fonden
Sweden
$19.5M -$269K -3,800 -1%
Truist Financial
255
Truist Financial
North Carolina
$19.4M +$3.89M +55,048 +26%
V
256
Veritable
Delaware
$19.4M -$241K -3,406 -1%
BF
257
BOK Financial
Oklahoma
$19.3M -$1.42M -20,112 -7%
BSA
258
Braun Stacey Associates
New York
$19.3M -$1.23M -17,395 -6%
SMDAM
259
Sumitomo Mitsui DS Asset Management
Japan
$19.2M -$4.44M -62,791 -19%
OC
260
Oppenheimer & Co
New York
$19M -$1.46M -20,642 -7%
VFA
261
Virtus Fund Advisers
Connecticut
$18.9M +$17.5M +248,234 +3,903%
PA
262
Pinnacle Associates
New York
$18.9M -$29.7K -421 -0.2%
Nordea Investment Management
263
Nordea Investment Management
Sweden
$18.8M +$2.66M +37,667 +17%
SAM
264
Silvercrest Asset Management
New York
$18.7M +$9.33K +132 +0.1%
Artisan Partners
265
Artisan Partners
Wisconsin
$18.7M +$3.25M +45,939 +22%
DILH
266
Dai-ichi Life Holdings
Japan
$18.6M -$507K -7,181 -3%
Mitsubishi UFJ Asset Management
267
Mitsubishi UFJ Asset Management
Japan
$18.3M +$486K +6,882 +3%
SW
268
SVB Wealth
Massachusetts
$18.3M -$2.32M -32,869 -12%
CLOS
269
Compagnie Lombard Odier SCmA
Switzerland
$18.2M -$357K -5,051 -2%
Nomura Asset Management
270
Nomura Asset Management
Japan
$18M -$162K -2,286 -0.9%
OPERF
271
Oregon Public Employees Retirement Fund
Oregon
$17.7M -$467K -6,612 -3%
JMPWA
272
JP Morgan Private Wealth Advisors
California
$17.7M +$48.7K +689 +0.3%
LTFS
273
Ladenburg Thalmann Financial Services
Florida
$17.6M +$1.95M +27,554 +13%
ABC
274
Associated Banc-Corp
Wisconsin
$17.5M -$277K -3,920 -2%
First Trust Advisors
275
First Trust Advisors
Illinois
$17.4M -$10.8M -153,465 -39%

BMY Hedge Fund Activity: Q2 2016 in Review

1,576 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q2 2016, worth a combined $90.9B — up 16% from $78B a quarter earlier.

Buyers outnumbered sellers: 114 funds opened new BMY positions and 43 closed out — a net gain of 71 holders — while 576 added to existing stakes and 640 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $495M. The largest seller was Royal London Asset Management, cutting an estimated $1.81B.

  • 1,576 institutional investors held Bristol-Myers Squibb (BMY) as of Q2 2016, up from 1,523 in Q1 2016.
  • Funds reported $90.9B of Bristol-Myers Squibb stock for Q2 2016, up 16% quarter-over-quarter.
  • 114 funds opened new Bristol-Myers Squibb positions in Q2 2016 and 43 closed out, a net change of +71 holders.
  • The largest Bristol-Myers Squibb buyer in Q2 2016 was T. Rowe Price Associates, an estimated $495M added.
  • The largest Bristol-Myers Squibb seller in Q2 2016 was Royal London Asset Management, an estimated $1.81B sold.

Based on aggregated 13F filings for Q2 2016.